OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Sphingomyelins and ceramides: possible biomarkers for dementia?	51
Genetic variation in apolipoprotein A-V in hypertriglyceridemia	50
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism	49
Editorial introductions	47
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review	39
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?	35
ANGPTL4: a new mode in the regulation of intravascular lipolysis	33
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	33
Alveolar macrophages: guardians of the alveolar lipid galaxy	30
Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?	28
Familial hypercholesterolemia in children and the importance of early treatment	28
Implementation science and genetic testing for familial hypercholesterolemia	28
Oxidized LDL receptors: a recent update	27
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19	25
Exosomes and lipid metabolism in metabolic and cardiovascular disorders	24
Lipid metabolism during pregnancy: consequences for mother and child	22
The lipid-heart hypothesis from the Seven Countries Study of Cardiovascular Diseases	22
Editorial introductions	22
Nonalcoholic fatty liver disease: an update	20
Splice correction therapies for familial hypercholesterolemic patients with low-density lipoprotein receptor mutations	18
Nutrition and its impact on cardiovascular disease	17
The current state of apolipoprotein E in dyslipidemia	16
A new SPRING in lipid metabolism	15
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia	15
Lipid effects of glucagon-like peptide 1 receptor analogs	15

Genetic determinants of pancreatitis risk in hypertriglyceridemia	15
Familial hypercholesterolemia in pregnancy	14
From clinical development to real-world outcomes with inclisiran	14
The need for national and international registries of patients with elevated lipoprotein(a)	13
APOE and familial hypercholesterolemia	13
High-density lipoprotein functionality, cardiovascular health, and patterns of alcohol consumption: new insights and future perspectives	13
The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion	13
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?	13
Can small dense LDL cholesterol be estimated from the lipid profile?	12
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent	12
Cardiomyocytes, sphingolipids and cardio myotoxicity	11
Newborn screening for lipid disorders	11
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?	11
Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies	10
The emerging role of fat-inducing transcript 2 in endoplasmic reticulum proteostasis and lipoprotein biogenesis	10
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	10
Editorial introductions	10
Distinct roles of size-defined HDL subpopulations in cardiovascular disease	10
Strategies for management of patients with elevated lipoprotein(a)	9
Clinical associations between exercise and lipoproteins	9
Pregnancy, cardiovascular health, and microchimerism	9
Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia	9
Genetic testing for familial hypercholesterolemia	9
Preprint servers in lipidology: current status and future role	9
Metabolic regulation of macrophage proliferation and function in atherosclerosis	8
Altered cardiovascular risk pattern of LDL cholesterol in older adults	8
The pathophysiology of excess plasma-free cholesterol	7
Clonal hematopoiesis of indeterminate potential and the evolutionary lottery in chromosome 2: does that make human atherosclerosis special?	7
The feedback cycles between glucose, amino acids and lipids and alpha cell secretion and their role in metabolic fatty liver disease	7
Prevention of cardiometabolic diseases through dietary modifications	7
Genotype–phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia	7
Assessment of cardiovascular disease risk: a 2023 update	7
LDL receptor-related protein 1 and its interacting partners in tissue homeostasis	7
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review	7
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment	7
Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients	6
Atherogenic low-density lipoprotein and cardiovascular risk	6
Lipids and peripheral neuropathy	6
Editorial introductions	6
Lipidomics in gestational diabetes mellitus	6
Genetic determinants of LDL cholesterol and risk of intracerebral haemorrhage	6
A contemporary snapshot of familial hypercholesterolemia registries	6
Dietary fat, telomere length and cognitive function: unravelling the complex relations	6
Recent lipoprotein(a) trials	6
How should low-density lipoprotein cholesterol be calculated in 2022?	5
Resolution of apolipoprotein A1 and A2 proteoforms: their cardiometabolic correlates and implications for future research	5
Therapeutic application of genome editing in dyslipidemia	5
Dietary factors and brain health	5
Translating guidelines into practice via implementation science: an update in lipidology	5
Remnant cholesterol as a new lipid-lowering target to reduce cardiovascular events	5

Editorial introduction	5
Triglyceride-rich lipoprotein cholesterol and cardiovascular risk	4
Diagnosis of remnant hyperlipidaemia	4
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	4
Genetics of remnant cholesterol	4
Predictors of cardiovascular risk in familial hypercholesterolemia	4
Cholesterol 25-hydroxylase expression following immune activation in response to SARS-CoV-2 infection	4
Regulation of cardiovascular calcification by lipids and lipoproteins	4
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action	4
Understanding the ins and outs of lipoprotein (a) metabolism	4
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations	4
Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism	4
Editorial introduction	3
Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy	3
Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery	3
Complex actions of sodium glucose transporter-2 inhibitors on lipids, calcific atherosclerosis, and bone density	3
Inflammation in atherosclerosis: a Big Idea that has underperformed so far	3
Cholesteryl ester transfer protein inhibition: a pathway to reducing risk of morbidity and promoting longevity	3
Polygenic contribution for familial hypercholesterolemia (FH)	2
Ketogenic therapies in mild cognitive impairment and dementia	2
Lipoprotein (a) in familial hypercholesterolaemia	2
Bempedoic acid: new evidence and recommendations on use	2
Editorial: Discussing polygenic risk with lipid clinic patients	2
G protein-coupled receptor 146: new insights from genetics and model systems	2
Increasing fruits and vegetables to reduce mortality and promote independence	2
Editorial introduction	2
Updates on genetics and molecular biology	2
Novel therapeutic opportunities for familial lecithin:cholesterol acyltransferase deficiency: promises and challenges	2
Circulating cell-free DNA and its association with cardiovascular disease: what we know and future perspectives	2
Lipids and brain inflammation in APOE4-associated dementia	2
PCSK9-directed therapies: an update	2
Dyslipidemia and aortic valve disease	2
Role of VLDL receptor in atherogenesis	2
Brain lipid metabolism: the emerging role of lipid droplets in glial cells	2
Fatty acid metabolism in cancer cells – the power of plasticity	2
Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management	2
Macrophage SR-B1 in atherosclerotic cardiovascular disease	2
Editorial introductions	2